A prospective non-interventional study to evaluate the performance of EASYCOV IVD as point-of-care (POC) test by comparing SARS-CoV-2 positive patients with SARS-CoV-2 negative controls on paired specimens (nasopharyngeal swabs & saliva samples).
A prospective non-interventional study to evaluate the performance of EASYCOV IVD as
point-of-care (POC) test by comparing SARS-CoV-2 positive patients with SARS-CoV-2 negative
controls on paired specimens (nasopharyngeal swabs & saliva samples).
The operators performing the diagnostic tests will be blinded from the RT-PCR results (i.e.
participant's group will be anonymized). Participants who have been tested by an
routineTurkish MOH and FDA EUA approved RT-PCR test using nasopharyngeal swabs will be
included in the study to perform the EASYCOV IVD tests in a POC setting.
Primary Objective:
• To evaluate the performance of EasyCov IVD as a point-of-care (POC) test performed on
saliva samples for the diagnosis of SARS-CoV-2 infection by comparing it to a Turkish MOH and
FDA EUA approved RT-PCR test performed on nasopharyngeal samples.
Secondary Objectives:
• Collection and storage of saliva samples, nasopharyngeal swabs at D0 to perform future
COVID-19 related research projects and validation of future generations of EASYCOV assays as
well as exploratory studies to find candidate biomarkers for Covid-19.
160 participants will be included in 1:1 ratio: 80 SARS-CoV-2 positive and 80 SARS-CoV-2
negative by a Turkish MOH and FDA approved RT-PCR IVD test
Diagnostic Test: EasyCov POC
Saliva samples will be collected according to the sampling protocol defined each for EASYCOV test. The EasyCoV test will be performed at the beginning of the study before obtaining the routine RT- PCR test results. The operators performing this test will be blinded from the routine RT-PCR results.
Inclusion Criteria:
Non-specific inclusion criteria:
1. Participant aged 18 and above
2. Participant agreeing to follow the study procedures
3. Participant able to understand the purpose, nature and methodology of the study
4. Participant having signed the informed consent
Specific inclusion criteria:
SARS-COV-2 positive patients - Participants tested positive for the SARS-COV-2 by the
routine Turkish MOH and FDA approved RT-PCR method.
SARS-COV-2 negative controls
- Participants tested negative for the SARS-COV-2 by the routine Turkish MOH and FDA
approved RT-PCR method.
Exclusion Criteria:
- Minors, persons deprived of their liberty, protected adults or vulnerable persons.
- Refusal to sign the consent.
Istanbul University Istanbul Faculty of Medicine (ITF)
Istanbul, Turkey
Investigator: Selçuk Şen
Rodwell Mkhwananzi, MD
+33 38 99 11 328
rodwell.mkhwananzi@firalis.com
Stéphanie Boutillier, PhD
stephanie.boutillier@amoneta-diagnostics.com
Arif Atahan, Prof.MD, Principal Investigator
Istanbul University Istanbul Faculty of Medicine (ITF), Turkey